Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, and various drug therapies, such as anticancer drugs, molecular-targeted drugs for VEGF and epidermal growth factor receptor, and immune checkpoint inhibitors have been developed [89]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.